Results 171 to 180 of about 4,258,326 (225)

Galectin-3 enhances monocyte-derived macrophage efferocytosis of apoptotic granulocytes in asthma

open access: yes
Background: Galectin-3 is a 32 kDa protein secreted by macrophages involved in processes such as cell activation, chemotaxis and phagocytosis. Galectin-3 has previously been shown to improve the ability of airway macrophages to ingest apoptotic cells ...
Melanie Erriah (6173654)   +7 more
core  

Mapping the Global Clinical Landscape of Pharmacological Therapies for Heart Failure With Preserved Ejection Fraction: An Analysis Based on ClinicalTrials.gov (2003–2025)

open access: yesiMetaMed, Volume 2, Issue 2, June 2026.
This study analyzed 236 heart failure with preserved ejection fraction (HFpEF) pharmacological trials registered on ClinicalTrials.gov from 2003 to 2025, revealing a post‐2016 surge (76.3%), U.S. dominance (58.5%), and prominence of SGLT2 inhibitors/novel therapies (each 13.1%).
Yucheng Hou   +6 more
wiley   +1 more source

Galectin-9 regulates dendritic cell polarity and uropod contraction by modulating RhoA activity. [PDF]

open access: yesJ Cell Biol
Franken GA   +18 more
europepmc   +1 more source

Role of galectin-9 in the development of gestational diabetes mellitus. [PDF]

open access: yesSci Rep
Albuayjan HHH   +16 more
europepmc   +1 more source

Inhibition of PLA2G15 Alleviates Palmitic Acid‐Induced Lysosomal Membrane Permeabilization in Human Nucleus Pulposus Cells During Intervertebral Disc Degeneration

open access: yesJOR SPINE, Volume 9, Issue 2, June 2026.
LMP is responsible for lysosomal dysfunction in IDD. The lipid composition changes in the lysosomal membrane, mediated by PLA2G15, are the cause of LMP. The C/EBPα significantly promotes PLA2G15 expression under PA overload stress. Inhibition of PLA2G15 alleviates PA‐induced LMP by inhibiting the hydrolysis of lysosomal membrane phospholipids. ABSTRACT
Liqun Duan   +7 more
wiley   +1 more source

Immune landscape characterization of neurofibromas with atypical features in Neurofibromatosis1 reveals PD-1 and the Tim-3/Galectin-9 pathway as potential therapeutic targets. [PDF]

open access: yesActa Neuropathol Commun
Brunet A   +14 more
europepmc   +1 more source

The Economic Burden of Metabolic Dysfunction‐Associated Steatohepatitis (MASH) With Cirrhosis: A Systematic Review

open access: yesLiver International Communications, Volume 7, Issue 2, June 2026.
ABSTRACT Background & Aims The clinical burden of metabolic dysfunction‐associated steatohepatitis (MASH) is substantial and there are no approved treatments for patients with cirrhosis. This systematic review aimed to better understand the economic burden in this population.
Jeffrey V. Lazarus   +8 more
wiley   +1 more source

Prognostic Impact and Clinicopathological Significance of TIM‐3 and LAG‐3 Expressions in Laryngeal Squamous Cell Carcinoma

open access: yesLaryngoscope Investigative Otolaryngology, Volume 11, Issue 3, June 2026.
ABSTRACT Introduction Research on immune checkpoint molecules is increasing, reflecting their critical role in cancer pathogenesis. While PD‐1, PD‐L1, and CTLA‐4 have been widely studied in head and neck cancers, outcomes remain unsatisfactory, highlighting the need for novel prognostic markers and therapeutic targets.
Fırat Tevetoğlu   +2 more
wiley   +1 more source

Soluble TIM-3 and galectin-9 predict survival in gastric and gastroesophageal junction cancer. [PDF]

open access: yesiScience
Digomann D   +20 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy